DUL Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Alnylam Pharmaceuticals Inc

Watchlist Manager

Watchlist

Price: 257.8 EUR -0.14% Market Closed

Market Cap: €19.9B

A	Alnylam Pharmaceuticals Inc XMUN:DUL	US
3	3M Co XMUN:MMM	US
	Great Southern Bancorp Inc F:GS6	US
L	Laboratory Corporation of America Holdings F:LAB	US

Profitability Summary

Alnylam Pharmaceuticals Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

81%

Strong 3Y Average Gross Margin

84%

Declining Gross Margin

84% > 81%

Healthy Operating Margin

17%

Negative 3Y Average Operating Margin

-9%

Operating Margin is Increasing

-76% > 17%

Healthy Net Margin

13%

Negative 3Y Average Net Margin

-16%

Net Margin is Increasing

-93% > 13%

Exceptional Free Cash Flow Margin

15%

Sustainable 3Y Average Free Cash Flow Margin

Free Cash Flow Margin is Increasing

-53% > 15%

Exceptional ROE

97%

Exceptional 3Y Average ROE

Negative 3Y Average ROIC

-10%

ROIC is Increasing

-72% > 40%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.